Company news
Kezar Life Sciences, Inc. (NASDAQ:KZR) news
Kezar Life Sciences, Inc. news releases on 6ix. Latest, Mar 12, 2026: Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical…
Press releases & updates
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
March 12, 2026
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
January 9, 2026
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
November 12, 2025
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
November 7, 2025
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
October 16, 2025
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
August 28, 2025
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
August 13, 2025
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
July 15, 2025
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
May 28, 2025
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
March 25, 2025
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
March 24, 2025
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
February 18, 2025
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 11, 2024
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
October 27, 2024
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
October 16, 2024
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
October 16, 2024
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
October 3, 2024
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
September 29, 2024
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 9, 2024
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 5, 2024
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
March 13, 2024
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 12, 2023
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
October 2, 2023
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia
September 19, 2023
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
August 9, 2023
Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
March 13, 2023
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023
March 12, 2023
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023
March 5, 2023
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
November 13, 2022
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
November 2, 2022
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis
October 2, 2022
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
July 10, 2022
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
June 26, 2022
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
May 2, 2022
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
March 16, 2022
Kezar Appoints Courtney Wallace to its Board of Directors
December 9, 2021
Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis
November 14, 2021
Kezar Reports Third Quarter Financial Results and Provides Business Update
November 8, 2021
Kezar to Host Virtual Investor and Analyst Day on November 15, 2021
November 2, 2021
Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies
October 26, 2021
Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs
October 4, 2021
Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis
August 22, 2021
Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates
August 11, 2021